Evidence map›Paper›PMID 38723166›Full record

SynthesisThe oncologist2024

Cognitive impairment following breast cancer treatments: an umbrella review.

Giulia Oliva, Andreina Giustiniani, Laura Danesin, Francesca Burgio, Giorgio Arcara, Pierfranco Conte

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Cancer-related cognitive impairment in adult cancer survivors: a clinical practice review for healthcare providers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Giulia OlivaDepartment of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padua, 35124 Padova, Italy.ORCID 0000-0002-9149-2105
Andreina GiustinianiIRCCS San Camillo Hospital, 30126 Venice, Italy.
Laura DanesinIRCCS San Camillo Hospital, 30126 Venice, Italy.
Francesca BurgioIRCCS San Camillo Hospital, 30126 Venice, Italy.
Giorgio ArcaraIRCCS San Camillo Hospital, 30126 Venice, Italy.
Pierfranco ConteIRCCS San Camillo Hospital, 30126 Venice, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCancer-related cognitive impairment (CRCI) refers to a cognitive decline associated with cancer or its treatments. While research into CRCI is expanding, evidence remains scattered due to differences in study designs, methodologies, and definitions. The present umbrella review aims to provide a comprehensive overview of the current evidence regarding the impact of different breast cancer therapies on cognitive functioning, with a particular focus on the interplay among objective cognitive deficits (ie, measured with standardized tests), subjective cognitive concerns, (ie, self-reported), and other mediating psycho-physical factors.

methodsThe search was made in Pubmed, Embase, and Scopus for articles published until July 2023, following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis protocol.

resultsChemotherapy and endocrine therapy appear consistently associated with CRCI in patients with breast cancer, primarily affecting memory, attention/concentration, executive functioning, and processing speed. Subjective cognitive concerns were often found weakly or not associated with neuropsychological test results, while overall CRCI seemed consistently associated with psychological distress, fatigue, sleep quality, and inflammatory and biological factors.

conclusionCurrent evidence suggests that CRCI is common after chemotherapy and endocrine therapy for breast cancer. However, heterogeneity in study designs and the scarcity of studies on more recent treatments such as targeted therapies and immunotherapies, highlight the need for more systematic and harmonized studies, possibly taking into account the complex and multifactorial etiology of CRCI. This may provide valuable insights into CRCI's underlying mechanisms and potential new ways to treat it.

Indexed as

Breast NeoplasmsCognitive DysfunctionFemaleHumansbreast cancercancer treatmentscognitive impairmentobjective cognitive deficitsquality of lifesubjective cognitive concerns

Identifiers

PMID38723166
PMCPMC11224991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.